Monte Rosa Therapeutics Inc. (GLUE) is a clinical-stage biotechnology company advancing a portfolio of molecular glue degraders (MGDs), a novel class of small molecules designed to harness the body's natural protein degradation pathways.
With three programs in clinical development, strategic collaborations with Novartis and Roche, and a proprietary discovery engine known as QuEEN (Quantitative and Engineered Elimination of Neosubstrates), the company is attempting to redefine therapeutic possibilities across oncology, immunology, and inflammation.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.